Common Contracts

Option Agreement and Plan of Merger BY AND among Fibrogen, Inc., Fortis therapeutics, Inc. and SHAREHOLDER REPRESENTATIVE SERVICES LLC, as Sellers’ Representative Dated as of JUNE 6, 2024

Option Agreement and Plan of Merger • August 6th, 2024 • Fibrogen Inc • Pharmaceutical preparations

• Contract Type
  Option Agreement and Plan of Merger
• Filed
  August 6th, 2024
• Company
  Fibrogen Inc
• Industry
  Pharmaceutical preparations

This First Amended and Restated Option Agreement and Plan of Merger (this “Option Agreement”) dated as of June 6, 2024 (the “Restatement Effective Date”) amends and restates that certain Option Agreement and Plan of Merger, effective as of May 5, 2023 (the “Original Effective Date” and such agreement, the “Original Agreement”), by and among FibroGen, Inc., a Delaware corporation (“FibroGen”), Fortis Therapeutics, Inc., a Delaware corporation (“Fortis”), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the Sellers’ Representative.

Option Agreement and Plan of Merger BY AND among Fibrogen, Inc., Fortis therapeutics, Inc. and SHAREHOLDER REPRESENTATIVE SERVICES LLC, as Sellers’ Representative Dated as of MAY 5, 2023

Option Agreement and Plan of Merger • August 7th, 2023 • Fibrogen Inc • Pharmaceutical preparations

• Contract Type
  Option Agreement and Plan of Merger
• Filed
  August 7th, 2023
• Company
  Fibrogen Inc
• Industry
  Pharmaceutical preparations

This Option Agreement and Plan of Merger (this “Option Agreement”) dated as of May 5, 2023, by and among FibroGen, Inc., a Delaware corporation (“FibroGen”), Fortis Therapeutics, Inc., a Delaware corporation (“Fortis”), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the Sellers’ Representative.